Taking two vaccine doses stays the most potent way to ensure protection against the COVID-19 Delta variant of concern (VOC), first discovered in India and now prevalent in the UK, concluded one of UK’s extensive studies of its kind. The study by scientists at the University of Oxford, comprising of more than 700,000 randomly chosen individuals from within the community, found that the Oxford/AstraZeneca and Pfizer/BioNTech vaccines still offer good safety against new infections.
The Oxford/AstraZeneca vaccine is being produced as Covishield in India and is also being administered in India.
The study also reveals that a single dose of the Moderna vaccine has similar or better effectiveness against the Delta variant as single doses of the other vaccines. Also, two doses of Pfizer/BioNTech have better initial effectiveness against new COVID-19 infections, but this drops quicker compared with two doses of Oxford/AstraZeneca.